Jobs / United States / Astrazeneca Pharmaceuticals Lp
Oncology Scientific Partnership Medical Director – (Onc SPMD) -Mid-Atlantic
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles15 certified filings for “Associate Director Oncology Outcomes Research” (Medical Scientists, Except Epidemiologists) in MD: $126k–$185k, median $140k. Most were filed at wage level II (47%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
Astra Zeneca is the place to build a world-class career. Here we are always looking to learn more, welcoming the varied opportunities to expand our horizons or develop niche expertise. Embrace the unparalleled access to industry-leading research, technology, and pipeline product launches with a footprint in every region. Coupled with our agility and sharp focus on talent development, there is an exciting opportunity to accelerate a rewarding and meaningful career. The Oncology Scientific Partnership Medical Director (SPMD) – US, Mid Atlantic [E. PA, W. VA, VA, MD, DC, DE], including NC is a member of the Center for Oncology Medical Partnerships within the US Medical Affairs team. In this role, you will develop and execute systems/institution specific plans for key sites, networks and pathways within your geographic region with focus on scientific, clinical, and evidence generation. This is a field-based role, reporting to the National Field Medical Director, Oncology SPMD. The successful candidate will be expected to live within their assigned geographic region. Utilizing your extensive expertise in oncology and account management you will define and implement a comprehensive medical strategy at identified priority US systems and networks. Successfully merging unique capabilities of assigned systems and networks with US Oncology Medical Affairs objectives. This role is part of a collaborative matrix team that partners closely across several functional areas within US Oncology, including but not limited to, Precision Medicine, Medical Science Liaisons (MSLs), Health Economics Outcomes Research (HEOR), Real World Evidence (RWE), Research & Development, External Alliances, National Oncology Account Director (NOAD) Team ,Clinical Trial Site Management and Monitoring ( SM&M) and related stakeholders. The SPMD will align with the NOAD and Account Director team in their assigned territories and serve as their medical partner in identified oncology specific accounts, oncology networks, oncology pathways and oncology group purchasing organizations/subsidiaries. The SPMD will champion innovative opportunities through interactions with Cancer Center Leaders (e.g., “C & D” suite) and other USMA staff on tumor specific opportunities. Major Responsibilities: · In conjunction with USMA franchise leadership, develop, support and drive US Oncology Medical Affairs strategy at assigned US-based health systems with a focus on innovation/enterprise-wide activities · Medical partner to NOAD and other Account Directors for priority US-based health systems, O-GPOs, oncology networks, oncology pathways and primary medical contact for leadership within assigned US-based health systems · Develop and maintain a clear medical account strategy plan including an enterprise-wide view that reflects the USMA, R&D, and oncology franchise objectives at assigned health systems · Lead through influence when collaborating with other internal stakeholders at AstraZeneca; including but not limited to SM&M, HEOR, RWE, MSLs, R&D, External Alliances, and Precision Medicine · Develop strong medical relationships across AstraZeneca functions and key scientific decision makers. · Act as the single point of contact for medical communications to leadership in assigned US-based health systems. · Responsible for coordinating AstraZeneca medical/scientific resources to support the needs of decision makers within assigned US-based health systems. · Develop and drive scientific information exchanges as needed in identified US-based health systems; Knowledge of all tumor types and encompassing entire AZ Oncology Portfolio · Utilizes knowledge of AstraZeneca matrix, institution and healthcare industry to strategically drive innovative solutions to patient care gaps in